Numinus Wellness Inc (TSE:NUMI) has released an update.
Numinus Wellness Inc. reports a decline in Q2 2024 with revenues falling 15.4% and gross profit down 22.7% from the previous quarter. Despite these challenges, the company doubled enrollment in its training programs and is focusing on operational optimization for future profitability. They have also submitted a Clinical Trial Application for MDMA-assisted psychotherapy post-quarter.
For further insights into TSE:NUMI stock, check out TipRanks’ Stock Analysis page.
